Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q1 2018 · 10-Q
Revenue$30.87M$30.87M+4.4% vs Q1 2017 Net Income-$27.46M-$27.46MN/M vs Q1 2017 EPS Diluted-$0.19-$0.19N/M vs Q1 2017 Gross Profit$3,749,000−3.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flow-$22,177,000N/M Free Cash Flowderived-$23,016,000N/M Margins · derivedGross margin12.1%−1.0 pt vs Q1 2017
Operating margin-76.8%+16.3 pt vs Q1 2017
Net margin-89.0%+22.3 pt vs Q1 2017
ended Mar 31, 2018 · filed May 10, 2018 · 40 d after period end